Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 2/2007

01-04-2007

Antiphospholipid Syndrome and Cognition

Authors: Bernardo Liberato, Roger A. Levy

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2007

Login to get access

Abstract

In addition to the well-defined neurologic events due to arterial and venous thrombotic vascular occlusions of antiphospholipid syndrome (APS), a broad spectrum of neuropsychiatric has been related to antiphospholipid (aPL). Experimental evidence of a pathogenic role of aPL in mice with impaired neurological function disclosed inflammatory reaction as a hallmark. The process that leads to neurological dysfunction seems to be both structurally destructive and functionally impairing. The most modern resources of neuroimmaging also suggest that, in addition to the micro-infarcts that occur in strategic areas, other metabolic impairments are related to progressive dementia and aPL presence. Although there is a lot of confusion among APS and lupus’ cognitive involvement, there is a body of experimental and clinical evidence that aPL causes this kind of damage.
Literature
1.
go back to reference Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 42:200–213PubMedCrossRef Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 42:200–213PubMedCrossRef
2.
go back to reference Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD (1997) Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 100(3):613–619PubMedCrossRef Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD (1997) Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 100(3):613–619PubMedCrossRef
3.
go back to reference Hess DC, Taormina M, Thompson J et al (1993) Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol 20(4):610–617PubMed Hess DC, Taormina M, Thompson J et al (1993) Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol 20(4):610–617PubMed
4.
go back to reference Shoenfeld Y, Nahum A, Korczyn AD et al (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442PubMedCrossRef Shoenfeld Y, Nahum A, Korczyn AD et al (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442PubMedCrossRef
5.
go back to reference Caronti B, Pittoni V, Palladini G, Valesini G (1998) Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 156(2):211–219PubMedCrossRef Caronti B, Pittoni V, Palladini G, Valesini G (1998) Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 156(2):211–219PubMedCrossRef
6.
go back to reference Caronti B, Calderaro C, Alessandri C et al (1998) Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 11(5):425–429PubMedCrossRef Caronti B, Calderaro C, Alessandri C et al (1998) Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 11(5):425–429PubMedCrossRef
7.
go back to reference Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD (1999) Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 8(2):127–133PubMedCrossRef Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD (1999) Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 8(2):127–133PubMedCrossRef
8.
go back to reference Cimaz R, Meroni PL, Shoenfeld Y (2006) Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughe’s syndrome). Lupus 15(4):191–197PubMedCrossRef Cimaz R, Meroni PL, Shoenfeld Y (2006) Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughe’s syndrome). Lupus 15(4):191–197PubMedCrossRef
9.
go back to reference Chinn RJ, Wilkinson ID, Hall-Craggs MA et al (1997) Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 40(1):36–46PubMedCrossRef Chinn RJ, Wilkinson ID, Hall-Craggs MA et al (1997) Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 40(1):36–46PubMedCrossRef
10.
go back to reference Kozora E, West SG, Kotzin BL et al (1998) Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 41(1):41–47PubMedCrossRef Kozora E, West SG, Kotzin BL et al (1998) Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 41(1):41–47PubMedCrossRef
11.
go back to reference Hilker R, Thiel A, Geisen C, Rudolf J (2000) Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus 9(4):311–316PubMedCrossRef Hilker R, Thiel A, Geisen C, Rudolf J (2000) Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus 9(4):311–316PubMedCrossRef
12.
go back to reference Sibbitt WL Jr, Haseler LJ, Griffey RR et al Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. Am J Neuroradiol YEAR 18:1271–1277 Sibbitt WL Jr, Haseler LJ, Griffey RR et al Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. Am J Neuroradiol YEAR 18:1271–1277
13.
go back to reference Sabet A, Sibbitt WL Jr, Stidley CA et al (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260PubMed Sabet A, Sibbitt WL Jr, Stidley CA et al (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260PubMed
14.
go back to reference Kozora E, Arciniegas DB, Filley CM et al (2005) Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 18(3):159–162PubMedCrossRef Kozora E, Arciniegas DB, Filley CM et al (2005) Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 18(3):159–162PubMedCrossRef
15.
go back to reference Appenzeller S, Li LM, Costallat L, Cendes F (2005) Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 128(12):2933–2940PubMedCrossRef Appenzeller S, Li LM, Costallat L, Cendes F (2005) Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 128(12):2933–2940PubMedCrossRef
16.
go back to reference Castellino G, Govoni M, Padovan M et al (2005) Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann Rheum Dis 64:1022–1027PubMedCrossRef Castellino G, Govoni M, Padovan M et al (2005) Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann Rheum Dis 64:1022–1027PubMedCrossRef
Metadata
Title
Antiphospholipid Syndrome and Cognition
Authors
Bernardo Liberato
Roger A. Levy
Publication date
01-04-2007
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2007
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-007-0007-x

Other articles of this Issue 2/2007

Clinical Reviews in Allergy & Immunology 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine